Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Moxonidine Rises Ramp Up In August

Pricewatch UK – August 2020

Executive Summary

Moxonidine topped our table of Biggest Risers for the second month in a row, as UK prices that had doubled in July accelerated even more rapidly in August.

You may also be interested in...



Moxonidine And Rasagiline See Triple-Digit Rises In July

Moxonidine led the price rises for established generics in the UK in July, with averages for the hypertension treatment more than doubling in some cases. However, among recently-launched products, rasagiline stood out with an average that was more than three times that of the previous month.

Exemestane Leads May Rises In UK

Exemestane led the steepest price rises for generics seen in the UK in May. However, concession pricing for the breast cancer drug overestimated the actual prices in the market recorded by WaveData.

Erythromycin And Paracetamol See April Rises In UK

Erythromycin and paracetamol were among the products with the steepest price rises in the UK in April, as the coronavirus pandemic continued to make its effects felt in the generics market.

Related Content

Topics

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel